ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Portfolio Pulse from
Rosen Law Firm is pursuing a securities class action lawsuit against Intellia Therapeutics, alleging that the company misled investors about its Phase 1/2 study for NTLA-3001 by not disclosing the declining demand for viral-based editing methods. The lawsuit covers the period from July 30, 2024 to January 8, 2025, with an important lead plaintiff deadline of April 14, 2025.
March 27, 2025 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The securities class action lawsuit could negatively impact Intellia's stock price by raising concerns about the company's transparency and the viability of its NTLA-3001 program.
The lawsuit directly targets Intellia Therapeutics and alleges material misrepresentations about its scientific program, which could damage investor confidence and potentially lead to financial penalties.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100